SB-509

DRUG5 trials

Sponsors

Sangamo Therapeutics

Conditions

Amyotrophic Lateral SclerosisDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy

Phase 2

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

CompletedNCT00406458

Sangamo TherapeuticsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy

Start: 2006-11-30End: 2009-05-31Updated: 2012-11-01

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

CompletedNCT00476931

Sangamo TherapeuticsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy

Start: 2007-05-31End: 2010-12-31Updated: 2012-11-01

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

CompletedNCT00665145

Sangamo TherapeuticsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy

Start: 2008-01-31End: 2009-10-31Updated: 2012-11-01

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT00748501

Sangamo TherapeuticsAmyotrophic Lateral Sclerosis

Start: 2008-09-30End: 2010-06-30Updated: 2012-11-01

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

CompletedNCT01079325

Sangamo TherapeuticsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy

Start: 2009-11-30End: 2016-04-30Updated: 2022-05-23